Epileptic Disorders


Clinical experience of abrupt discontinuation of perampanel: a case series Volume 23, numéro 1, February 2021

  • [1] Schmidt D. Starting, choosing, changing, and discontinuing drug treatment for epilepsy patients. Neurol Clin. 2016;34:363-381.
  • [2] Ranganathan LN, Ramaratnam S. Rapid versus slow withdrawal of antiepileptic drugs. Cochrane Database Syst Rev 2006; (2): CD005003.
  • [3] Abou-Khalil B., Lazenby B. Longterm experience with levetiracetam. Epileptic Disord. 2003;5:S33-S37. 1
  • [4] Bidlack J.M., Morris H.H. Phenobarbital withdrawal seizures may occur over several weeks before remitting: human data and hypothetical mechanism. Seizure. 2009;18:79-81.
  • [5] Hanada T., Hashizume Y., Tokuhara N., Akenaka O., Kohmura N., Ogasawara A. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52:1331-1340. 7
  • [6] European Medicines Agency. Fycompa summary of product characteristics. London, United Kingdom, 2012.
  • [7] Food and Drug Administration. Fycompa prescribing information. Silver Springs, MD, 2012.
  • [8] Steinhoff B.J. The AMPA receptor antagonist perampanel in the adjunctive treatment of partial onset seizures: clinical trial evidence and experience. Ther Adv Neurol Disord. 2015;8:137-147. 3
  • [9] Rogawski M., Yang H., Fant R., Williams W., Xing D., Dobrinsky C. Perampanel Discontinuation Is Not Associated With Self-Reported Withdrawal Symptoms in Patients Completing Phase III Clinical Studies (Abstract). Neurology. 2015;84:P1.232. 14
  • [10] Steinhoff B.J., Hübers E., Kurth C., Jürges U. Plasma concentration and clinical effects of perampanel - the Kork experience. Seizure. 2019;67:18-22.
  • [11] Gidal B.E., Laurenza A., Hussein Z., Yang H., Fain R., Edelstein J. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology. 2015;84:1972-1980.
  • [12] Raol Y.H., Zhang G., Budreck E.C., Brooks-Kayal A.R. Long-term effects of diazepam and phenobarbital treatment during development on GABA receptors, transporters and glutamic acid decarboxylase. Neuroscience. 2005;132:399-407.